Functionalizing bioinks for 3D bioprinting applications.

Abstract:

:3D bioprinting has emerged as the intersection between chemistry, biology and technology. Through its integration of cells, biocompatible materials and robotic-controlled dispensing systems, the process enables the production of structures that are biomimetic and functional, thus revolutionizing the concept of tissue engineering. One of the biggest limitations of 3D bioprinting for tissue engineering is the lack of printable materials (bioinks) with all-inclusive properties desirable for the construction of engineered 'bio-physico-functional' tissues and organs. Thus, bioinks are required to be functionalized or altered to produce the most desirable bioarchetypes. Functionalization methods vary across chemical, mechanical, physical and biological methods, and common methods include blending of materials, coatings, crosslinking and exploiting functional groups. In this short review, a description and critical comparison of reported functionalization methods, focusing on their effects and contributions toward bioinks, have been presented.

journal_name

Drug Discov Today

journal_title

Drug discovery today

authors

Parak A,Pradeep P,du Toit LC,Kumar P,Choonara YE,Pillay V

doi

10.1016/j.drudis.2018.09.012

subject

Has Abstract

pub_date

2019-01-01 00:00:00

pages

198-205

issue

1

eissn

1359-6446

issn

1878-5832

pii

S1359-6446(18)30243-5

journal_volume

24

pub_type

杂志文章,评审
  • Novel therapeutic investigational strategies to treat severe and disseminated HSV infections suggested by a deeper understanding of in vitro virus entry processes.

    abstract::The global burden of herpes simplex virus (HSV) legitimates the critical need to develop new prevention strategies, such as drugs and vaccines that are able to fight either primary HSV infections or reactivations. Moreover, the ever-growing number of patients receiving transplants increases the number of severe HSV in...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2016.03.003

    authors: Clementi N,Criscuolo E,Cappelletti F,Burioni R,Clementi M,Mancini N

    更新日期:2016-04-01 00:00:00

  • New avenues to target Wnt/β-catenin signaling.

    abstract::Wnt/β-catenin signaling is an evolutionarily conserved signaling cascade with imperative roles during development and in adult stem cell maintenance. Hyperactivation of Wnt/β-catenin drives various cancers, whereas hypoactivation underlies bone malformations and neurodegenerative disorders. Although several small mole...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2010.11.007

    authors: Verkaar F,Zaman GJ

    更新日期:2011-01-01 00:00:00

  • Targeting VEGF-neuropilin interactions: a promising antitumor strategy.

    abstract::Inhibition of vascular endothelial growth factor (VEGF) or its corresponding receptor (VEGFR) has been validated as an efficacious antiangiogenetic approach for cancer treatment. More recently, neuropilins (NRPs), the essential coreceptors for VEGF, have also been shown to have a significant role in VEGF signaling. Gi...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2018.10.004

    authors: Peng K,Bai Y,Zhu Q,Hu B,Xu Y

    更新日期:2019-02-01 00:00:00

  • Optimizing the use of open-source software applications in drug discovery.

    abstract::Drug discovery is a time consuming and costly process. Recently, a trend towards the use of in silico computational chemistry and molecular modeling for computer-aided drug design has gained significant momentum. This review investigates the application of free and/or open-source software in the drug discovery process...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/S1359-6446(05)03692-5

    authors: Geldenhuys WJ,Gaasch KE,Watson M,Allen DD,Van der Schyf CJ

    更新日期:2006-02-01 00:00:00

  • Regeneration of stalled immune responses to transformed and infected cells using γδ T cells.

    abstract::Manipulation of the human immune system is becoming more of a therapeutic focus as a treatment option or complement. Prominent examples are the increasing use of monoclonal antibodies in combating malignant tumours, and the numerous adoptive immunotherapy trials underway. One important aspect of any use of the human i...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2014.03.021

    authors: Gustafsson K,Anderson J,Fisher JPH,Yan M

    更新日期:2014-06-01 00:00:00

  • Genomic microarrays in the spotlight.

    abstract::Microarray-based comparative genomic hybridization (array-CGH) has emerged as a revolutionary platform, enabling the high-resolution detection of DNA copy number aberrations. In this article we outline the use and limitations of genomic clones, cDNA clones and PCR products as targets for genomic microarray constructio...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:

    authors: Mantripragada KK,Buckley PG,de Ståhl TD,Dumanski JP

    更新日期:2004-12-15 00:00:00

  • Modulating target engagement of small molecules via drug delivery: approaches and applications in drug discovery and development.

    abstract::Drug-delivery technologies for modified drug release have been in existence for decades, but their utilization has been largely limited to post-launch efforts improving therapeutic outcomes. Recently, they have gained renewed importance because the pharmaceutical industry is steadily shifting to a more integrated disc...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2020.12.008

    authors: Yang W,Bhattachar SN,Patel PJ,Landis M,Patel D,Reid DL,Duvnjak Romic M

    更新日期:2020-12-14 00:00:00

  • Modified release drug delivery in veterinary medicine.

    abstract::To successfully research and develop an animal pharmaceutical dosage form, a diverse array of issues covering basic medicine, pharmacology and technology must be addressed. Societal concerns regarding animal and public health, as well as the rapidly changing farming and economic environments, provide additional challe...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/s1359-6446(02)02362-0

    authors: Rathbone MJ,Martinez MN

    更新日期:2002-08-01 00:00:00

  • Novel approaches to the pharmacotherapy of pulmonary arterial hypertension.

    abstract::Pulmonary arterial hypertension (PAH) has evolved from an untreatable condition to a disease for which several classes of drugs have now been approved, including various prostanoids, endothelin receptor antagonists and phosphodiesterase-5 inhibitors. Because the pathogenesis of pulmonary hypertension is increasingly u...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2008.12.003

    authors: Olsson KM,Hoeper MM

    更新日期:2009-03-01 00:00:00

  • Ion-channel assay technologies: quo vadis?

    abstract::Although many existing methods are used to study the functions of ion channels and to screen lead compounds for important ion-channel targets, new technologies are being developed for improved performance. It is important to identify the advantages and disadvantages of each technology. In this review, we segment the i...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(01)02095-5

    authors: Xu J,Wang X,Ensign B,Li M,Wu L,Guia A,Xu J

    更新日期:2001-12-15 00:00:00

  • Cancer therapy via modulation of micro RNA levels: a promising future.

    abstract::Micro RNAs (miRNAs) are a class of naturally occurring ∼ 22 nt long non-coding small RNA molecules that regulate the expression of a wide range of genes involved in development, growth, proliferation and apoptosis. miRNAs are evolutionarily conserved from plants to animals, and they regulate and fine-tune a diverse ar...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2010.07.003

    authors: Kota SK,Balasubramanian S

    更新日期:2010-09-01 00:00:00

  • Accelerating biomedical innovation: a case study of the SPARK program at Stanford University, School of Medicine.

    abstract::Translating academic medical research into new therapies is an important challenge for the biopharmaceutical industry and investment communities, which have historically favored later-stage assets with lower risk and clearer commercial value. The Stanford SPARK program is an innovative model for addressing this challe...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.03.015

    authors: Kim ES,Omura PMC,Lo AW

    更新日期:2017-07-01 00:00:00

  • Translation of drug effects from experimental models of neuropathic pain and analgesia to humans.

    abstract::Neuropathic pain research remains a challenging undertaking owing to: (i) the lack of understanding about the underlying disease processes; and (ii) poor predictive validity of the current models of evoked pain used for the screening of novel compounds. Common consensus is that experimental models replicate symptoms (...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2012.02.010

    authors: Taneja A,Di Iorio VL,Danhof M,Della Pasqua O

    更新日期:2012-08-01 00:00:00

  • New tools for functional genomic analysis.

    abstract::For the past decade, the development of genomic technology has revolutionized modern biological research and drug discovery. Functional genomic analyses enable biologists to perform analysis of genetic events on a global scale and they have been widely used in gene discovery, biomarker determination, disease classific...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2009.05.005

    authors: Chen X,Jorgenson E,Cheung ST

    更新日期:2009-08-01 00:00:00

  • Designed covalent allosteric modulators: an emerging paradigm in drug discovery.

    abstract::Covalent allosteric modulators possess the pharmacological advantages (high potency, extended duration of action and low drug resistance) of covalent ligands and the additional benefit of the higher specificity and lower toxicity of allosteric modulators. This approach is gaining increasing recognition as a valuable t...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2016.11.013

    authors: Lu S,Zhang J

    更新日期:2017-02-01 00:00:00

  • Commercially bioavailable proprietary technologies and their marketed products.

    abstract::In this review, we discuss the methodologies and platform technologies for enhancing the oral bioavailability of poorly soluble drugs. We also highlight the mechanisms of formulation technologies for improving desired physicochemical attributes of active substances. We focus on various commercial technologies, along w...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2013.05.007

    authors: Alam MA,Al-Jenoobi FI,Al-Mohizea AM

    更新日期:2013-10-01 00:00:00

  • Recent progress in antiretrovirals--lessons from resistance.

    abstract::Recent failures in efforts to develop an effective vaccine against HIV-1 infection have emphasized the importance of antiretroviral therapy in treating HIV-1-infected patients. Thus far, inhibitors of two viral enzymes, reverse transcriptase and protease, have had a profoundly positive impact on the survival of HIV-1-...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2008.02.003

    authors: Adamson CS,Freed EO

    更新日期:2008-05-01 00:00:00

  • Cancer cell senescence: a new frontier in drug development.

    abstract::Senescence forms a universal block to tumorigenesis which impacts on all hallmarks of cancer, making it an attractive target for drug discovery. Therefore a strategy must be devised to focus this broad potential into a manageable drug discovery programme. Several issues remain to be addressed including the lack of rob...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2012.01.019

    authors: Cairney CJ,Bilsland AE,Evans TR,Roffey J,Bennett DC,Narita M,Torrance CJ,Keith WN

    更新日期:2012-03-01 00:00:00

  • Cervical cancer and HPV infection: ongoing therapeutic research to counteract the action of E6 and E7 oncoproteins.

    abstract::Cervical cancer is the fourth most common cancer among women worldwide and its development is mainly associated with human papillomavirus infection, a highly sexually transmissible virus. The expression of E6 and E7 viral oncoproteins deregulates cell repairing mechanisms through impairment of tumor suppressor protein...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2019.07.011

    authors: Almeida AM,Queiroz JA,Sousa F,Sousa Â

    更新日期:2019-10-01 00:00:00

  • FDA-approved drug labeling for the study of drug-induced liver injury.

    abstract::Drug-induced liver injury (DILI) is a leading cause of drugs failing during clinical trials and being withdrawn from the market. Comparative analysis of drugs based on their DILI potential is an effective approach to discover key DILI mechanisms and risk factors. However, assessing the DILI potential of a drug is a ch...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2011.05.007

    authors: Chen M,Vijay V,Shi Q,Liu Z,Fang H,Tong W

    更新日期:2011-08-01 00:00:00

  • Use of Benford's law in drug discovery data.

    abstract::Benford's law states that the distribution of the first digit of many data sets is not uniform. The first digit of any random number will be 1 almost 30% of the time, and larger digits occur as the first digit with lower and lower frequency, to the point where 9 occurs as a first digit only 5% of the time. Here, we de...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2010.03.003

    authors: Orita M,Moritomo A,Niimi T,Ohno K

    更新日期:2010-05-01 00:00:00

  • Engineered miniaturized models of musculoskeletal diseases.

    abstract::The musculoskeletal system is an incredible machine that protects, supports and moves the human body. However, several diseases can limit its functionality, compromising patient quality of life. Designing novel pathological models would help to clarify the mechanisms driving such diseases, identify new biomarkers and ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2016.04.015

    authors: Bersini S,Arrigoni C,Lopa S,Bongio M,Martin I,Moretti M

    更新日期:2016-09-01 00:00:00

  • The multiple therapeutic applications of miRNAs for bone regenerative medicine.

    abstract::With the aging of the general population, there is an increasing need for bone defect repair, prompting the development of reliable alternatives to autologous bone grafting, without the usually associated major drawbacks (i.e., limited volume and severe postoperative pain). Given the crucial role that miRNAs appear to...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.04.007

    authors: Scimeca JC,Verron E

    更新日期:2017-07-01 00:00:00

  • Drug-induced liver injury severity and toxicity (DILIst): binary classification of 1279 drugs by human hepatotoxicity.

    abstract::Drug-induced liver injury (DILI) is of significant concern to drug development and regulatory review because of the limited success with existing preclinical models. For developing alternative methods, a large drug list is needed with known DILI severity and toxicity. We augmented the DILIrank data set [annotated usin...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2019.09.022

    authors: Thakkar S,Li T,Liu Z,Wu L,Roberts R,Tong W

    更新日期:2020-01-01 00:00:00

  • Recent developments in natural product-based drug discovery for tuberculosis.

    abstract::Natural products (NPs) have been at the origin of several established drugs against tuberculosis (TB). Although the current clinical TB pipeline does not feature any candidates derived from new NP scaffolds, numerous novel NPs or NP analogs have been discovered in the recent past with promising activity against Mycoba...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2016.11.015

    authors: Dong M,Pfeiffer B,Altmann KH

    更新日期:2017-03-01 00:00:00

  • A novel approach to identifying antiarrhythmic drug targets.

    abstract::Sudden cardiac death, secondary to ventricular fibrillation (VF), remains the leading cause of death in the USA. Recent experimental and theoretical studies suggest that VF could be caused by spiral wave re-entry. The initiation and subsequent break-up of spiral waves has been linked to electrical alternans, a phenome...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/s1359-6446(02)02567-9

    authors: Gilmour RF Jr

    更新日期:2003-02-15 00:00:00

  • Designing a bio-inspired biomimetic in vitro system for the optimization of ex vivo studies of pancreatic cancer.

    abstract::Pancreatic cancer is one of the most aggressive and lethal human malignancies. Drug therapies and radiotherapy are used for treatment as adjuvants to surgery, but outcomes remain disappointing. Advances in tissue engineering suggest that 3D cultures can reflect the in vivo tumor microenvironment and can guarantee a ph...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.01.012

    authors: Totti S,Vernardis SI,Meira L,Pérez-Mancera PA,Costello E,Greenhalf W,Palmer D,Neoptolemos J,Mantalaris A,Velliou EG

    更新日期:2017-04-01 00:00:00

  • Discovery of cytokine mimics using cell-based systems.

    abstract::The successful cloning and subsequent clinical application of recombinant cytokines and/or growth factors has generated a number of important therapeutics. In contrast to the G-protein-coupled receptors, identification of small-molecule agonists of the cytokine and/or growth factor receptor family has proved difficult...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(00)00062-3

    authors: Miller SG

    更新日期:2000-12-01 00:00:00

  • Organoid-on-a-chip and body-on-a-chip systems for drug screening and disease modeling.

    abstract::In recent years, advances in tissue engineering and microfabrication technologies have enabled rapid growth in the areas of in vitro organoid development as well as organoid-on-a-chip platforms. These 3D model systems often are able to mimic human physiology more accurately than traditional 2D cultures and animal mode...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2016.07.003

    authors: Skardal A,Shupe T,Atala A

    更新日期:2016-09-01 00:00:00

  • Raising the bar in anticancer therapy: recent advances in, and perspectives on, telomerase inhibitors.

    abstract::Telomerase is a ribonucleic reverse transcriptase enzyme that uses an integral RNA component as a template to add tandem telomeric DNA repeats, TTAGGG, at the 3' end of the chromosomes. 85-90% of human tumors and their derived cell lines predominantly express high levels of telomerase, therefore contributing to cancer...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2019.05.015

    authors: Saraswati AP,Relitti N,Brindisi M,Gemma S,Zisterer D,Butini S,Campiani G

    更新日期:2019-07-01 00:00:00